Modulation of epidermal growth factor heterodimer activity

• US 8,323,987 B2
• Filed: 02/17/2005
• Issued: 12/04/2012
• Est. Priority Date: 02/17/2004
• Status: Expired due to Fees

• Current Assignee: University of North Carolina At Chapel Hill (University of North Carolina System)
• Original Assignee: University of North Carolina At Chapel Hill (University of North Carolina System)
• Inventors: Threadgill, David, Lee, Daekee
• Primary Examiner(s): Dent, Alana Harris
• Application Number:
  US10/584,960
• Publication Number:
  US 20100015124A1
• Time in Patent Office: 2,847 Days
• Field of Search: None
• US Class Current: 436/538
• CPC Class Codes: C07K 14/71 for growth factors; for growth regulators
• CPC Class Codes: C07K 16/2863 against receptors for growth factors, growth regulators
• CPC Class Codes: C07K 16/32 against translation products of oncogenes
• CPC Class Codes: C07K 2317/622 Single chain antibody (scFv)
• CPC Class Codes: G01N 2333/485 Epidermal growth factor [EGF] (urogastrone)
• CPC Class Codes: G01N 2500/00 Screening for compounds of potential therapeutic value
• CPC Class Codes: G01N 33/74 involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Abstract

Provided is a method for screening a plurality of compounds for an ability to bind to a heterodimer of EGFR and another ERBB family member. Also provided are compounds that bind to heterodimers of EGFR and another ERBB family member, and methods of using the identified compounds to suppress the growth of a tumor associated with EGFR heterodimer activity in a subject.

Claims

1. A method for screening a plurality of compounds for an ability to bind to a heterodimer of EGFR and another ERBB family member, the method comprising:

(a) contacting a first structure comprising an EGFR/ERBB heterodimer with a first solution, the first solution comprising the plurality of compounds, wherein the EGFR/ERBB heterodimer comprises an ERBB family member comprising the amino acid sequence set forth in SEQ ID NO;

6;

(b) removing any compounds bound to the first structure to produce a second solution;

(c) contacting a second structure comprising an EGFR homodimer with the second solution, wherein the first structure and the second structure are identical except that the second structure does not contain an ERBB family member other than EGFR; and

(d) recovering any unbound compounds to produce a third solution,

whereby a compound that binds to a heterodimer of EGFR and another ERBB family member is identified.

2. The method of claim 1, wherein the plurality of compounds comprises a plurality of antibodies.

3. The method of claim 2, wherein the plurality of compounds comprises phage-displayed antibodies.

4. The method of claim 3, wherein the plurality of compounds comprises a phage-displayed antibody library.

5. The method of claim 4, wherein the phage-displayed antibody library comprises a phage-displayed single chain variable fragment (scFv) library or a phage-displayed Fab library.

6. The method of claim 3, wherein the phage-displayed antibodies are humanized.

7. The method of claim 1, wherein the first structure comprises a cell that expresses EGRF and the ERBB family member comprising the amino acid sequence set forth in SEQ ID NO:

6, or an isolated membrane fraction of said cell.

8. The method of claim 7, wherein the cell is a recombinant cell that does not normally express any ERBB family member or ErbB ligand, but has been engineered to express a human EGFR and at least one other human ERBB family member.

9. The method of claim 1, wherein the second structure comprises a cell that expresses EGRF but no other ERBB family member, or an isolated membrane fraction of said cell.

10. The method of claim 9, wherein the cell is a recombinant cell that does not normally express any ERBB family member or ErbB ligand, but has been engineered to express a human EGFR.

11. The method of claim 1, further comprising:

(a) contacting a third structure comprising an EGFR/ERBB heterodimer with the third solution, wherein the EGFR/ERBB heterodimer comprises an ERBB family member comprising the amino acid sequence set forth in SEQ ID NO;

6; and

(b) detecting binding of a compound to the EGFR/ERBB heterodimer on the third structure.

12. The method of claim 1, further comprising negatively selecting the plurality of compounds by contacting the plurality of compounds with a structure that is identical to the first and second structures except that it does not contain any ERBB family members.